This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Leo E. Hollister, MD
Harris County Psychiatric Center University of Texas Health Science Center 2800 S MacGregor Way PO Box 20249 Houston, TX 77225-0249

Kenneth Krajewski, MD; Terry Rustin, MD; Hamp Gillespie, PhD
Houston, Tex

Arch Gen Psychiatry. 1992;49(11):905.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

A recent letter to the ARCHIVES reported some modestly favorable results in treating cocaine dependence in methadone-treated patients with buproprion hydrochloride.¹ Starting from a different theoretical basis, we embarked on a double-blind evaluation of buproprion vs placebo in patients being treated only for cocaine dependence. Buproprion was chosen because, like cocaine, it is a high-affinity dopamine uptake inhibitor but, unlike cocaine, produces no euphoria or dependence. Thus, it might act to mitigate the actions of cocaine.²

We planned to exploit our 28-day inpatient treatment program to monitor the course of treatment in this study for a period of 21 days. Our limited goal was to determine whether buproprion might reduce craving for cocaine during this period. Our patients were largely young (median age, 27 years), male (38 men and eight women), inner city youth who were of low socioeconomic class and borderline intelligence (mean IQ, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?